We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
I Agree
Email registered. Please sign in.×
Enter your contact to build trust with supplier(s)×
One More Step to Finalize Your Registration
An activation link has been sent to your email address.
Please check the email and activate your account now. It might take few minutes to get the email.
If you did not find it, please check your spam box.
Having problem receiving the email? Send again
Still cannot receive? Contact us
Email ：PharmaSources@imsinoexpo.com
Whatsapp ：+86-13621645194
Allsino Pharmaceutical Co., Ltd. was founded in 2004 by a group of aspiring chemists with extensive experiences in both US and China pharmaceutical industry. In December 2016，Allsino merged with Sinopep but continues to operate independently as a 100% subsidiary company of Sinopep-Allsino Biopharmaceuticals. As premier Contract Development and Manufacturing Organization (CDMO), Allsino offers worldwide clients an intergraded and exclusive customer synthesis service of small molecules from preclinical to commercial stage. Over the years, Allsino Pharmaceutical has demonstrated deep understanding of synthetic chemistry and powerful production capability to meet customers’ complicate needs.
Main Competitive Advantages: International Approvals/Standards,Experienced R&D Staff,Production Capacity,Contract Manufacturing (CRO,CMO),Small Orders Accepted,Quality Service
Other Competitive Advantages:
Patents and Copyrights:
Business Type: Manufacturer
R&D capacity: Own Brand
Annual Turnover(USD): 500,000 to 99,999,999
Main Sales Markets: North America,Western Europe,Eastern Europe
Audited Supplier
![Tert-butyl 2,4-dichloro-5,8-dihydropyrido[3,4-d]pyrimidine-7(6H)-carboxylate](https://eimg.pharmasources.com/image/20241205/1QyWNjQPQC3O88I4U2g5FHc94QPvfQoI1ntcDtT1.png!280)
![4-Methyl-7-H-pyrrolo[2,3-d]pyrimidine](https://eimg.pharmasources.com/image/20241205/7GTTgwC7T16o5XW2YWiTh0lgYbxTxulYPVECgbbG.png!280)
Pharma Sources Insight June 2024: Globalization on the Go
![4-Methyl-7-H-pyrrolo[2,3-d]pyrimidine](https://eimg.pharmasources.com/image/20241205/7GTTgwC7T16o5XW2YWiTh0lgYbxTxulYPVECgbbG.png!200)
![Tert-butyl 2,4-dichloro-5,8-dihydropyrido[3,4-d]pyrimidine-7(6H)-carboxylate](https://eimg.pharmasources.com/image/20241205/1QyWNjQPQC3O88I4U2g5FHc94QPvfQoI1ntcDtT1.png!200)
![Tert-butyl (1S,4S,5R)-5-amino-2-azabicyclo[2.1.1]hexane-2-carboxylate](https://eimg.pharmasources.com/image/20241205/3is0ZGMF39UP5rg54C1yqN4KMOa6HV9d6wX101rA.png!200)
![Tert-butyl (1R,4R,5S)-5-amino-2-azabicyclo[2.1.1]hexane-2-carboxylate](https://eimg.pharmasources.com/image/20241205/b2DDFdlfoKcAhYr4ewYpeEIhpRouGL3fJgfknFvt.png!200)
![Dimethyl bicyclo[2.2.2]octane-1,4-dicarboxylate](https://eimg.pharmasources.com/image/20241205/XhP4ITQ9PiE4QZfy0UO9wEHbncMT1UbpsAy1ggMz.png!200)
![Dimethyl (1r,4r)-bicyclo[2.2.1]heptane-1,4-dicarboxylate](https://eimg.pharmasources.com/image/20240703/SHIfKGzVvlGa0jNTRens2GOHw3SDSbLgfqDejdFv.png!200)
